{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:25:36Z","timestamp":1788013536894,"version":"build-2784847793"},"reference-count":17,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,8,15]]},"abstract":"<jats:p>The report describes a patient who presented to our centre with abdominal pain and significant weight loss due to adenocarcinoma of the tail of the pancreas. The cancer was deemed as \u2018resectable disease associated with morbid surgical outcomes\u2019 due to the local involvement of the vessels and adjacent organs. Given the patient\u2019s excellent performance status, the patient underwent neoadjuvant chemotherapy with folinic acid, fluorouracil, irinotecan and oxaliplatin to downstage the tumour for less morbid surgical resection. The patient underwent 12 cycles of chemotherapy with serial imaging which demonstrated positive response to treatment and surgical resection was performed. Surgical pathology revealed no residual tumour and imaging was negative for any extrapancreatic tumour metastasis. This is an unusual case as pancreatic malignancy is usually lethal with poor survival outcomes.<\/jats:p>","DOI":"10.1136\/bcr-2018-225621","type":"journal-article","created":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T12:35:18Z","timestamp":1535805318000},"page":"bcr-2018-225621","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Pathological complete response in pancreatic adenocarcinoma with FOLFIRINOX"],"prefix":"10.1136","volume":"2018","author":[{"given":"Chien-Ting","family":"Kao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4305-5701","authenticated-orcid":false,"given":"Anup","family":"Kasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,9,1]]},"reference":[{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.2","unstructured":"National Cancer Institute, 2018. Cancer Statistics Review, 1975-2014 - SEER Statistics. cited 19 Feb 2018. https:\/\/seer.cancer.gov\/csr\/1975_2014\/"},{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.5553"},{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds224"},{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.5553"},{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4251\/wjgo.v7.i10.241","article-title":"Management of borderline resectable pancreatic cancer","volume":"7","author":"Mahipal","year":"2015","journal-title":"World J Gastrointest Oncol"},{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/07357900701206356","article-title":"Neoadjuvant therapy in pancreatic cancer","volume":"25","author":"Quiros","year":"2007","journal-title":"Cancer Invest"},{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.8","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1200\/JCO.1997.15.3.928","article-title":"Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas","volume":"15","author":"Spitz","year":"1997","journal-title":"J Clin Oncol"},{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.9","doi-asserted-by":"crossref","unstructured":"Conroy T . FOLFIRINOX versus gemcitabine in patients with metastatic pancreatic cancer. Canc\u00e9ro digest 2011;4.doi:10.4267\/2042\/45859","DOI":"10.4267\/2042\/45859"},{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369"},{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.11","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.13131184"},{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.12","doi-asserted-by":"crossref","first-page":"e161137","DOI":"10.1001\/jamasurg.2016.1137","article-title":"Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer","volume":"151","author":"Katz","year":"2016","journal-title":"JAMA Surg"},{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.13","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1245\/s10434-016-5373-2","article-title":"Systematic review of resection rates and clinical outcomes after folfirinox-based treatment in patients with locally advanced pancreatic cancer","volume":"23","author":"Rombouts","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.14","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.3892\/ol.2017.6026","article-title":"Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: a case report","volume":"13","author":"Palmarocchi","year":"2017","journal-title":"Oncol Lett"},{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.15","first-page":"1","article-title":"Complete pathologic response of pancreatic adenocarcinoma to chemotherapy (FOLFIRINOX) is not equal to cure: case report and review of the literature","volume":"1","author":"Pozza","year":"2016","journal-title":"Clinics in Oncology"},{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.16","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1186\/s12885-016-2821-0","article-title":"Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review","volume":"16","author":"Gostimir","year":"2016","journal-title":"BMC Cancer"},{"key":"2025042706073959000_2018.sep01_1.bcr-2018-225621.17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.pan.2014.07.002","article-title":"Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature","volume":"14","author":"Valeri","year":"2014","journal-title":"Pancreatology"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-225621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T13:07:54Z","timestamp":1745759274000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-225621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":17,"alternative-id":["10.1136\/bcr-2018-225621"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-225621","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}